The thalassaemia syndromes

被引:42
作者
Birgens, Henrik
Ljung, Rolf
机构
[1] Herlev Univ Hosp, Dept Haematol, DK-2730 Herlev, Denmark
[2] Malmo Univ Hosp, Dept Paediat, Malmo, Sweden
关键词
thalassaemias; genotype-phenotype relationships; pathophysiology; treatment;
D O I
10.1080/00365510601046417
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The thalassaemia syndromes, endemic in the Mediterranean area, the Middle East, the Indian subcontinent, the Far East and in tropical Africa, are the most common hereditary disorders in humans, and millions of people are affected by diseases. Due to a widespread population flow between continents in recent past centuries, the thalassaemias are now occurring with relatively high frequency in many non-endemic areas. In the Nordic countries, homozygous thalassaemia is still relatively rare, and most health-care personnel are not familiar with these diseases. This article focuses on two important issues, namely the biological and the clinical aspects of thalassaemia.
引用
收藏
页码:11 / 25
页数:15
相关论文
共 71 条
[1]   Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia [J].
Anderson, LJ ;
Wonke, B ;
Prescott, E ;
Holden, S ;
Walker, JM ;
Pennell, DJ .
LANCET, 2002, 360 (9332) :516-520
[2]   Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload [J].
Anderson, LJ ;
Holden, S ;
Davis, B ;
Prescott, E ;
Charrier, CC ;
Bunce, NH ;
Firmin, DN ;
Wonke, B ;
Porter, J ;
Walker, JM ;
Pennell, DJ .
EUROPEAN HEART JOURNAL, 2001, 22 (23) :2171-2179
[3]   Global epidemiology of hemoglobin disorders [J].
Angastiniotis, M ;
Modell, B .
COOLEYS ANEMIA: SEVENTH SYMPOSIUM, 1998, 850 :251-269
[4]   Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation [J].
Angelucci, E ;
Muretto, P ;
Nicolucci, A ;
Baronciani, D ;
Erer, B ;
Gaziev, J ;
Ripalti, M ;
Sodani, P ;
Tomassoni, S ;
Visani, G ;
Lucarelli, G .
BLOOD, 2002, 100 (01) :17-21
[5]   The laboratory diagnosis of haemoglobinopathies [J].
Bain, BJ ;
Amos, RJ ;
Bareford, D ;
Chapman, C ;
Davies, SC ;
Old, JM ;
Wild, BJ .
BRITISH JOURNAL OF HAEMATOLOGY, 1998, 101 (04) :783-792
[6]   α-thalassaemia [J].
Bernini, LF ;
Harteveld, CL .
BAILLIERES CLINICAL HAEMATOLOGY, 1998, 11 (01) :53-90
[7]   Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major [J].
Borgna-Pignatti, C ;
Cappellini, MD ;
De Stefano, P ;
Del Vecchio, GC ;
Forni, GL ;
Gamberini, MR ;
Ghilardi, R ;
Piga, A ;
Romeo, MA ;
Zhao, HQ ;
Cnaan, A .
BLOOD, 2006, 107 (09) :3733-3737
[8]   EFFICACY OF DEFEROXAMINE IN PREVENTING COMPLICATIONS OF IRON OVERLOAD IN PATIENTS WITH THALASSEMIA MAJOR [J].
BRITTENHAM, GM ;
GRIFFITH, PM ;
NIENHUIS, AW ;
MCLAREN, CE ;
YOUNG, NS ;
TUCKER, EE ;
ALLEN, CJ ;
FARRELL, DE ;
HARRIS, JW .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (09) :567-573
[9]   GENOTYPE-PHENOTYPE CORRELATIONS IN BETA-THALASSEMIAS [J].
CAO, A ;
GALANELLO, R ;
ROSATELLI, MC .
BLOOD REVIEWS, 1994, 8 (01) :1-12
[10]   Iron-chelating therapy with the new oral agent ICL670 (Exjadee®) [J].
Cappellini, MD .
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2005, 18 (02) :289-298